EUVIMEDEUVIMED entdecken
Vergleichsstudie

Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study

Yuki Okita, Yoshimitsu Shimomura, Sho Komukai, Ling Zha, Masayo Komatsu, Yasuyoshi Kimura, Yasufumi Gon, Fumiko Murata iD, Megumi Maeda, Kosuke Kiyohara, Tetsuhisa Kitamura iD, Haruhisa Fukuda

International Journal of Geriatric Psychiatry · 2025-01 · 40 (1)

DOI: 10.1002/gps.70036 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Geriatric Psychiatry, 2025-01. Verfasst von Yuki Okita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Environmental Medicine and Population Sciences, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japa…. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Dementia, Cholinergic Antagonists, Adrenergic beta-3 Receptor Agonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: JST FOREST Program, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Anticholinergic drugs can cause cognitive impairment. The risk of dementia associated with anticholinergics compared to beta‐3 agonists (mirabegron and vibegron) has not been extensively investigated in the super‐aging society of Japan. This study evaluated the association between the dementia risk and anticholinergics compared to beta‐3 agonists in older adults with overactive bladder in Japan.

Methods

This study had 1,493,202 participants from the Longevity Improvement & Fair Evidence Study, which includes claim data in Japan from 2014 to 2022. The participants included 13,448 anticholinergic drug users and 24,669 beta‐3 agonist users diagnosed with overactive bladder and aged ≥ 65 years. The Cox proportional hazards regression model was used to calculate hazard ratios and 95% confidence intervals being adjusted for confounding variables to evaluate the impact of anticholinergic drugs compared to beta‐3 agonists prescribed at index date to patients with overactive bladder.

Results

Among the beta‐3 agonist and anticholinergic drug users, the mean (standard deviation) age was 78.9 (6.7) and 78.8 (7.0) years, and the percentage of men was 47.2% and 39.7%, respectively. In the beta‐3 agonist group, 2130 participants were newly diagnosed with dementia during the 51,605 person‐years of follow‐up from the index date, whereas in the anticholinergic drug group, 1826 participants were diagnosed during the 34,929 person‐years of follow‐up. In the Cox proportional hazard regression model, there was an increased risk of dementia in the anticholinergic drug group compared to the beta‐3 agonist group (adjusted hazard ratio [aHR] = 1.22; 95% confidence interval [CI], 1.15–1.30). The increased risk remained identical when Inverse Probability Weighting (IPW) model was used for the analysis (aHR = 1.19; 95% CI, 1.11–1.28).

Conclusions

Compared to beta‐3 agonists, anticholinergic drugs are associated with an increased risk of dementia in older adults with overactive bladder, in Japan. These findings suggest that beta‐3 agonists may have a lower risk of dementia than anticholinergics and have potential to be a good alternative opinion for older people with OAB, which warrants further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveDementiaCholinergic AntagonistsAdrenergic beta-3 Receptor AgonistsProportional Hazards ModelsHumansMaleFemaleAgedJapanAged, 80 and overRisk Factors

Stichwörter der Autor:innen

anticholinergicsbeta‐3 agonistsdementiaelderly populationoveractive bladderretrospective cohort study

Substanzen

Cholinergic AntagonistsAdrenergic beta-3 Receptor Agonists

Autor:innen und Institutionen

  • Division of Environmental Medicine and Population Sciences, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Department of Food Science, Faculty of Home Economics, Otsuma Women's University, Tokyo, Japan.

ORCID-Profile: Fumiko Murata, Tetsuhisa Kitamura

Förderung

  • JST FOREST Program
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Okita, Y., Shimomura, Y., Komukai, S., Zha, L., Komatsu, M., Kimura, Y., Gon, Y., Murata, F., Maeda, M., Kiyohara, K., Kitamura, T., & Fukuda, H. (2025). Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study. International Journal of Geriatric Psychiatry, 40(1). https://doi.org/10.1002/gps.70036

Vancouver

Okita Y, Shimomura Y, Komukai S, Zha L, Komatsu M, Kimura Y, et al. Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study. International Journal of Geriatric Psychiatry. 2025;40(1). doi:10.1002/gps.70036

BibTeX
@article{Okita2025,
  author = {Okita, Yuki and Shimomura, Yoshimitsu and Komukai, Sho and Zha, Ling and Komatsu, Masayo and Kimura, Yasuyoshi and Gon, Yasufumi and Murata, Fumiko and Maeda, Megumi and Kiyohara, Kosuke and Kitamura, Tetsuhisa and Fukuda, Haruhisa},
  title = {Risks of Dementia Associated With Anticholinergic Medication Compared to Beta‐3 Agonist Among Older Patients With Overactive Bladder in Japan: The LIFE Study},
  journal = {International Journal of Geriatric Psychiatry},
  year = {2025},
  volume = {40},
  number = {1},
  doi = {10.1002/gps.70036}
}
Kostenlos starten →